168 related articles for article (PubMed ID: 8862015)
21. Preoperative chemotherapy for soft-tissue sarcomas of the extremities.
Pezzi CM; Pollock RE; Evans HL; Lorigan JG; Pezzi TA; Benjamin RS; Romsdahl MM
Ann Surg; 1990 Apr; 211(4):476-81. PubMed ID: 2157378
[TBL] [Abstract][Full Text] [Related]
22. Results of isolated regional perfusion in the treatment of malignant soft tissue tumors of the extremities.
Hoekstra HJ; Schraffordt Koops H; Molenaar WM; Oldhoff J
Cancer; 1987 Oct; 60(8):1703-7. PubMed ID: 2820562
[TBL] [Abstract][Full Text] [Related]
23. SAS amplification in soft tissue sarcomas.
Smith SH; Weiss SW; Jankowski SA; Coccia MA; Meltzer PS
Cancer Res; 1992 Jul; 52(13):3746-9. PubMed ID: 1319830
[TBL] [Abstract][Full Text] [Related]
24. P-glycoprotein expression in soft-tissue sarcomas.
Nakanishi H; Myoui A; Ochi T; Aozasa K
J Cancer Res Clin Oncol; 1997; 123(6):352-6. PubMed ID: 9222302
[TBL] [Abstract][Full Text] [Related]
25. Comparative evaluation by semiquantitative reverse transcriptase polymerase chain reaction of MDR1, MRP and GSTp gene expression in breast carcinomas.
Lacave R; Coulet F; Ricci S; Touboul E; Flahault A; Rateau JG; Cesari D; Lefranc JP; Bernaudin JF
Br J Cancer; 1998 Mar; 77(5):694-702. PubMed ID: 9514046
[TBL] [Abstract][Full Text] [Related]
26. Aberrant expression of cell-cycle regulatory proteins in human mesenchymal neoplasia.
Creager AJ; Cohen JA; Geradts J
Cancer Detect Prev; 2001; 25(2):123-31. PubMed ID: 11341347
[TBL] [Abstract][Full Text] [Related]
27. High-level expression of podoplanin in benign and malignant soft tissue tumors: immunohistochemical and quantitative real-time RT-PCR analysis.
Xu Y; Ogose A; Kawashima H; Hotta T; Ariizumi T; Li G; Umezu H; Endo N
Oncol Rep; 2011 Mar; 25(3):599-607. PubMed ID: 21234520
[TBL] [Abstract][Full Text] [Related]
28. Malignant fibrous histiocytoma: the most common soft-tissue sarcoma.
Makepeace AR; Cannon SR
Br J Hosp Med; 1988 Feb; 39(2):122, 124, 126-7. PubMed ID: 2833967
[TBL] [Abstract][Full Text] [Related]
29. In vitro and in vivo expression of somatostatin receptors in intermediate and malignant soft tissue tumors.
Florio T; Montella L; Corsaro A; De Chiara A; Apice G; Fazioli F; Lastoria S; Schettini G; Palmieri G
Anticancer Res; 2003; 23(3B):2465-71. PubMed ID: 12894529
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of P-glycoprotein in heat- and/or drug-resistant hepatoma variants.
Pirity M; Hevér-Szabó A; Venetianer A
Cytotechnology; 1996; 19(3):207-14. PubMed ID: 8862008
[TBL] [Abstract][Full Text] [Related]
31. Multidrug resistance phenotype in the RMS-GR human rhabdomyosarcoma cell line obtained after polychemotherapy.
Prados J; Melguizo C; Marchal JA; Vélez C; Alvarez L; Aránega A
Jpn J Cancer Res; 1999 Jul; 90(7):788-93. PubMed ID: 10470293
[TBL] [Abstract][Full Text] [Related]
32. [Expression of MDR1 and GST-pi in osteosarcoma and soft tissue sarcoma and their correlation with chemotherapy resistance].
Wei L; Song XR; Wang XW; Li M; Z uo WS
Zhonghua Zhong Liu Za Zhi; 2006 Jun; 28(6):445-8. PubMed ID: 17152492
[TBL] [Abstract][Full Text] [Related]
33. p53 gene mutations and p53 protein expression in human soft tissue sarcomas.
Yoo J; Lee HK; Kang CS; Park WS; Lee JY; Shim SI
Arch Pathol Lab Med; 1997 Apr; 121(4):395-9. PubMed ID: 9140310
[TBL] [Abstract][Full Text] [Related]
34. PML expression in soft tissue sarcoma: prognostic and predictive value in alkylating agents/antracycline-based first line therapy.
Vincenzi B; Santini D; Schiavon G; Frezza AM; Silletta M; Crucitti P; Casali P; Dei Tos AP; Rossi S; Rizzo S; Badalamenti G; Tomasino RM; Russo A; Butrynski JE; Tonini G
J Cell Physiol; 2012 Apr; 227(4):1657-62. PubMed ID: 21678421
[TBL] [Abstract][Full Text] [Related]
35. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.
Eggermont AM; Schraffordt Koops H; Klausner JM; Kroon BB; Schlag PM; Liénard D; van Geel AN; Hoekstra HJ; Meller I; Nieweg OE; Kettelhack C; Ben-Ari G; Pector JC; Lejeune FJ
Ann Surg; 1996 Dec; 224(6):756-64; discussion 764-5. PubMed ID: 8968230
[TBL] [Abstract][Full Text] [Related]
36. Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells.
Stein U; Walther W; Shoemaker RH
J Natl Cancer Inst; 1996 Oct; 88(19):1383-92. PubMed ID: 8827016
[TBL] [Abstract][Full Text] [Related]
37. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins.
Plaat BE; Hollema H; Molenaar WM; Torn Broers GH; Pijpe J; Mastik MF; Hoekstra HJ; van den Berg E; Scheper RJ; van der Graaf WT
J Clin Oncol; 2000 Sep; 18(18):3211-20. PubMed ID: 10986053
[TBL] [Abstract][Full Text] [Related]
38. Role of gene amplification in drug resistance.
Schoenlein PV
Cancer Treat Res; 1994; 73():167-200. PubMed ID: 7710905
[No Abstract] [Full Text] [Related]
39. Transcriptional regulation of multidrug resistance gene expression.
Thorgeirsson SS; Gant TW; Silverman JA
Cancer Treat Res; 1994; 73():57-68. PubMed ID: 7710910
[No Abstract] [Full Text] [Related]
40. Infrequent mutation of the p16/MTS1 gene and overexpression of cyclin-dependent kinase 4 in human primary soft-tissue sarcoma.
Yao J; Pollock RE; Lang A; Tan M; Pisters PW; Goodrich D; El-Naggar A; Yu D
Clin Cancer Res; 1998 Apr; 4(4):1065-70. PubMed ID: 9563903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
